Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03883113
Other study ID # FLU010
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date June 3, 2019
Est. completion date April 17, 2020

Study information

Verified date March 2021
Source Vaccitech Limited
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A Phase 2, single center, randomized, double blind study evaluating the safety, efficacy, and immunogenicity of MVA NP+M1 in the H3N2 human influenza challenge model; on healthy adult volunteers.


Description:

The study consists of an outpatient vaccination phase (155 participants), and at least 2 months later an inpatient challenge phase (134 participants). Participants are randomized 93:62 to receive either MVA-NP+M1 or Placebo. Up to 20 participants will be challenged over several 3-week blocks, and the remainder at the final 3-week block for a total of 80 MVA-NP+M1 and 54 Placebo recipients challenged.


Recruitment information / eligibility

Status Completed
Enrollment 145
Est. completion date April 17, 2020
Est. primary completion date December 16, 2019
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 55 Years
Eligibility Inclusion Criteria: - Healthy males and females aged =18 and =55 years of age at the point of enrolment. - Non-smokers or those who stopped smoking = 3 months prior to screening 1 visit. - Willingness to remain in isolation for the duration of the study. - A female participant is eligible for this study if she is not pregnant or breast feeding and 1 of the following: 1. Of non-childbearing potential (i.e., women who have had a hysterectomy or tubal ligation or are postmenopausal, as defined by no menses in greater than or equal to 1 year). 2. Of childbearing potential but has been and agrees to continue practicing highly effective contraception or abstinence (if this is the preferred and usual lifestyle of the participant) from 6 months prior to vaccination to 6 months after administration of the influenza challenge virus. Highly effective methods of contraception include 1 or more of the following: i. male partner who is sterile (vasectomised) prior to the female participants entry into the study and is the sole sexual partner for the female participant; ii. hormonal (oral, intravaginal, transdermal, implantable or injectable); iii. an intrauterine hormone-releasing system (IUS); iv. an intrauterine device (IUD) with a documented failure rate of < 1%; v. bilateral tubal occlusion. - Pre-challenge serum microneutralization test (MNT) against A/Belgium/4217/2015 (H3N2) challenge strain < 20. Exclusion Criteria: - BMI < 19 and > 32. - Presence of any significant acute or chronic, uncontrolled medical (or psychiatric) illness including a history of chronic respiratory illness. - History of seasonal hay fever or a clinically significant seasonal allergic rhinitis (SAR), including the use of symptomatic prescription only medication and non-prescription medication. - History or evidence of autoimmune disease or known immunodeficiency of any cause - with the exception of atopic dermatitis/eczema and atopic rhinitis. - Any history of anaphylaxis in reaction to vaccination or history of allergic reactions likely to be exacerbated by any component of the vaccine. - History of lung disease (Asthma, COPD). - Current smokers or those who stopped smoking < 3months prior to screening 1 visit. - Positive diagnostic tests for HIV, Hepatitis B or Hepatitis C indicating active infection. - Evidence of drug abuse or a positive urine drug screen or alcohol breath test. - Chronic use of any medication or other product (prescription or over-the-counter), for symptoms of rhinitis or nasal congestion or for any chronic nasopharyngeal complaint, or chronic use of any intranasal medication for any indication that has not ceased within 30 days prior to screening 1. - Receipt of any investigational drug within 3 months prior to vaccination, or prior participation in a clinical trial of any influenza vaccine, or any investigational vaccine or experimental influenza viral challenge delivered directly to the respiratory tract within 1 year prior to challenge. - Receipt of the 2018/2019 seasonal flu vaccine. - Receipt of any live vaccines within the 4 weeks prior to vaccination. - Any laboratory test which is abnormal and which is deemed by the Investigator(s) to be clinically significant. - Receipt of any systemic chemotherapy agent at any time. - Physician reported influenza or a syndrome consistent with influenza (as judged by the investigator) in the previous 6 months. - Known allergy to treatments for influenza (including but not limited to oseltamivir). - History of frequent epistaxis (nose bleeds). - Any nasal or sinus surgery within 6 months of Viral Challenge or any significant abnormality, either of which results in alteration of the anatomy of the nose or nasopharynx (including significant nasal polyps). - Volunteers with household contacts who are at risk for serious or severe complications of influenza disease including, but not limited to: persons = 65 years; presence of significant chronic cardiopulmonary, metabolic, renal, or neurological conditions; immunosuppression due to any condition or therapies; BMI >40. - Participants that are an employee or family member of the Investigator or study site personnel may not be enrolled. - Any other finding that, in the opinion of the Investigator, deems the participant unsuitable for the study. EXCLUSION (CHALLENGE PERIOD ONLY) - Abnormal spirometry assessed to be clinically significant. - Known close contact with anyone known to have influenza in the past 7 days at the time of quarantine. - Influenza-like illness (ILI) symptoms as assessed at the admission to clinic on Day -2 prior to challenge. - Presence of fever, defined as participant presenting with a temperature reading of > 38.0°C on admission to quarantine. - Qualitative Polymerase chain reaction (PCR) results positive for viral infection. However, participants may be included into later challenge cohort. - Acute use of any medication or other product, prescription or over-the-counter, for symptoms of rhinitis or nasal congestion within 7 days prior to challenge. This includes any oral corticosteroid or beta agonist containing nasal spray.

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
MVA-NP+M1
Trial Vaccine
Saline
Sodium Chloride Placebo
H3N2 (A/Belgium/2417/2015)
Challenge Agent

Locations

Country Name City State
Belgium SGS Life Sciences, Clinical Pharmacology Unit (CPU) Antwerp

Sponsors (1)

Lead Sponsor Collaborator
Vaccitech Limited

Country where clinical trial is conducted

Belgium, 

Outcome

Type Measure Description Time frame Safety issue
Other Severity of Individual Symptoms for MVA-NP+M1 vs. Placebo Severity of individual self-reported symptoms for MVA-NP+M1 vs. Placebo 11 days
Other Total Symptom Score Time to Start, Time to Peak and Duration Time to start; time to peak and duration of total self-reported symptom score, regardless of take rate
Influenza Symptom Score Card of FLU010 - Solicited symptoms for generalized, and upper and lower respiratory tract symptoms scored by severity (0: absent, 1: mild, 2: moderate, or 3: severe).
11 days
Other Correlation of T Cell Phenotypes With Illness Outcomes Correlation of antigen specific T Cell phenotypes with illness outcomes 3 months
Other Vaccination Effect on Antibody Responses by ELISpot and ICS Assays Antibody responses of MVA-NP+M1 vs Placebo following influenza challenge measured by ELISpot and Intracellular Cytokine Staining (ICS) 3 months
Primary Degree of Nasopharyngeal Viral Shedding as Determined by Quantitative Polymerase Chain Reaction qPCR Measure of nasopharyngeal viral shedding during challenge; recorded as viral area under curve (vAUC) as determined by quantitative real time polymerase chain reaction (qRT-PCR). vAUC is calculated by plotting the log viral particles number/ml for each time point against time and is using the trapezoidal rule. Throughout 9 days (Day2, Day3, Day4, Day5, Day6, Day7, Day8, Day9, Day10) after viral Inoculation (Day1) of the challenge phase. Nasal swabs taken twice a day (b.i.d) at least 8 hours apart.
Secondary Number and Percentage of Virologically Confirmed Influenza-Like Illness Incidence (frequency tabulation) of laboratory-confirmed influenza-like illness compared between vaccine and placebo arms Virologically confirmed influenza-like illness (ILI) is defined as having respiratory or flu-like symptom occurring on two consecutive days, along with a positive qPCR or qCulture result. 9 days from day 2 to day 10
Secondary Percentage of Participants With Attack Rate of Challenge Agent (qRT-PCR) The attack rate is defined as the percentage of inoculated participants with at least two consecutive positive swabs as determined by qRT-PCR within the timespan of two consecutive days 9 days from day 2 to day 10
Secondary Percentage of Participants With Quantitative Culture Attack Rate of Challenge Agent (qCulture) The attack rate is defined as the percentage of inoculated participants with at least two consecutive positive swabs as determined by qCulture within the timespan of two consecutive days 9 days from day 2 to day 10
Secondary Time to Start of Viral Shedding (qPCR) From Virus Inoculation The Time to Start of Viral Shedding (qPCR) is calculated as (datetime of first of two positive swabs (qPCR) within 2 consecutive days - challenge datetime)/(60*60) 9 days from day 2 to day 10
Secondary Time to Start of Viral Shedding (qCulture) From Virus Inoculation Time to Start of Viral Shedding (qCulture) is calculated as (datetime of first of two positive swabs (qCulture) within 2 consecutive days - challenge datetime)/(60*60) 9 days from day 2 to day 10
Secondary Peak Viral Shedding (qPCR) After the Virus Inoculation This is measured by the highest viral load concentration by qPCR 9 days from Day 2 to Day 10
Secondary Peak Viral Shedding (qCulture) After Virus Inoculation This is measured by the highest viral load concentration by qCulture. 9 days from day 2 to day 10
Secondary Time to Peak of Viral Shedding (qPCR) From the Viral Inoculation This is calculated as (datetime of highest viral load concentration (qPCR) - challenge datetime)/(60*60) 9 days from day 2 to day 10
Secondary Time to Peak of Viral Shedding (qCulture) From the Viral Inoculation This is calculated as (datetime of highest viral load concentration (qCulture) - challenge datetime)/(60*60) 9 days from day 2 to day 10
Secondary Duration of Viral Shedding (qPCR) After the Virus Inoculation It is calculated as (datetime of first negative swab (qPCR) following the last positive swab (qPCR) - datetime of first positive of two positive swabs (qPCR) within 2 consecutive days)/(60*60) 9 days from day2 to day10
Secondary Duration of Viral Shedding (qCulture) After the Virus Inoculation It is calculated as (datetime of first negative swab (qCulture) following the last positive swab (qCulture) - datetime of first positive of two positive swabs (qCulture) within 2 consecutive days)/(60*60) 9 days from day 2 to day 10
Secondary Total Area Under the Curve (AUC) of Self-reported Influenza Total Symptom Score (SSC AUC) Total symptom scores were compared for MVA-NP+M1 vs. Placebo from Day1 to Day11 post-challenge as AUC of composite score.
Symptoms were collected twice a day (lymphadenopathy once a day) on a Symptom Score Card(SSC).
SSC recorded scores for each 16 general (gastrointestinal/body systemic) and 12 local (upper/lower respiratory tract) symptoms, on the scale per timepoint (for example Day2,AM).
Participants rated the severity of symptoms, higher scores indicating a more severe symptom.
The scores ranged from 0 to 3 (0:symptom free, 1:mild, 2:moderate, 3:severe).The SSC also contained the question whether the subject felt well to go to work "today" (yes/no). The Overall SSC score was calculated, as the Arithmetic Mean of the Scores collected across all 28 items on the card per Timepoint and ranged from 0 to maximum 3.
The SSC AUC [0-11 days] was derived based on the Overall SSC score against time (*hour), using the linear trapezoidal rule and it ranged from 0 to 110 Score*hour.
11 days from Day 1 to Day 11
Secondary Total Days of Fever Total days of fever for MVA-NP+M1 vs. Placebo 11 days from Day 1 to Day 11
Secondary Average Total Mucus Production Total mucus weight of used tissue (regardless of take rate) for MVA-NP+M1 vs. Placebo.
Total mucus production was only be calculated in case all tissues were returned (sum of clean and used tissues returned should be 20 tissues for each bag).
11 days from Day 1 to Day 11
Secondary T Cell Responses as Defined by ELISpot Assay in Relation to the Primary Endpoint, Symptom Scores and Influenza Incidence T Cell Response was assessed for IFN gamma and granzyme B, on the peripheral blood mononuclear cell using a double-colour enzymatic ELISpot assay.
For each of them, three stimulation antigens were assessed: nucleoprotein NP, matrix1 M1 and a negative control, dimethyl sulfoxide (DMSO).
The number of spot-forming T cell colonies per well (i.e. 200,000 cells) +/- standard deviation for the total response to NP+M1 is reported.
The endpoint was recorded as the mean spot-forming units per million peripheral blood mononuclear cells in the peptide-stimulated wells minus the mean DMSO control wells for the sample. T cell responses over time (sampling timepoints) were then assessed in relation to the primary endpoint, symptom scores, and influenza incidence.
3 months (day 0, day 8 and day 28 of the vaccination period and day -1 and day 28 of the challenge period)
Secondary Number of Participants With MVA-NP+M1 Vaccination Related Adverse Events and Symptoms, Measured by Self-reported Symptoms Occurrence of solicited local and systemic reactogenicity signs and symptoms for 7 days following vaccination; self-reported symptoms recorded using paper diaries 7 days following vaccination
Secondary Number of Participants With H3N2 Challenge Related Adverse Events and Symptoms, Measured by Self-reported Symptoms Occurrence of solicited local and systemic reactogenicity signs and symptoms; self-reported symptoms recorded using questionnaires and adverse event monitoring 17 days following vaccination
See also
  Status Clinical Trial Phase
Completed NCT05523089 - The Effectiveness of CD388 to Prevent Flu in an Influenza Challenge Model in Healthy Adults Phase 2
Completed NCT05009251 - Using Explainable AI Risk Predictions to Nudge Influenza Vaccine Uptake N/A
Completed NCT03282240 - Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Participants ≥65 Years in the US Phase 3
Completed NCT00968526 - Study to Evaluate Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) in Adults Phase 3
Completed NCT00971425 - Evaluation of the Immune Response and the Safety of a Pandemic Influenza Candidate Vaccine (H1N1) Phase 3
Completed NCT00968539 - Study to Evaluate the Immunogenicity & Safety of an Investigational Influenza Vaccine (H1N1) in Adults Phase 3
Completed NCT05525494 - Patient Portal Flu Vaccine Reminders (5) N/A
Completed NCT04074928 - Safety and Immunogenicity Study of QIVc in Healthy Pediatric Subjects Phase 3
Completed NCT04695717 - This Study Was Conducted to Evaluate the Safety and Immunogenicity of IVACFLU-S Produced in Children From 6 Months to Under 18 Years Old and the Elderly Over 60 Years Old in Vietnam Phase 3
Completed NCT05012163 - Lottery Incentive Nudges to Increase Influenza Vaccinations N/A
Completed NCT04109222 - Collection of Serum Samples From Children and Older Adults Receiving the 2019-2020 Formulations of Fluzone® Quadrivalent and Fluzone® High-Dose Influenza Vaccines, Respectively Phase 4
Completed NCT03888989 - Response to Influenza Vaccine During Pregnancy Phase 1
Completed NCT02587221 - Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared to Non-influenza Vaccine Comparator in Adults ≥ 65 Years of Age Phase 3
Completed NCT03453801 - The Role of CD4+ Memory Phenotype, Memory, and Effector T Cells in Vaccination and Infection Phase 1
Completed NCT01440387 - A Study of Immunogenicity and Safety of GSK Biologicals' Influenza Vaccine FLU-Q-QIV in Adults Aged 18 Years and Older Phase 3
Terminated NCT01195779 - Trial to Evaluate Safety and Immunogenicity of GSK Biologicals' Influenza Vaccine GSK2584786A in Healthy Children Phase 2
Completed NCT03321968 - Lot-to-lot Consistency of a Plant-Derived Quadrivalent Virus-Like Particles Influenza Vaccine in Healthy Adults Phase 3
Completed NCT00972517 - Study to Evaluate the Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) in Children Phase 3
Completed NCT04570904 - Broadening Our Understanding of Early Versus Late Influenza Vaccine Effectiveness
Recruiting NCT03331991 - Prevention of Influenza and Other Wintertime Respiratory Viruses Among Healthcare Professionals in Israel N/A